Clinical experience with cabazitaxel in prostate cancer
Research type
Research Study
Full title
Clinical experience with cabazitaxel in patients with metastatic castrate resistant prostate cancer (ECLIPSE)
IRAS ID
171062
Contact name
Helen Cardy
Contact email
Sponsor organisation
Sanofi UK
Duration of Study in the UK
0 years, 9 months, 31 days
Research summary
Prostate cancer is the most common cancer in men, and the second leading cause of cancer death in men in the UK. Over time many men experience disease progression despite androgen blockade treatment. This is known as metastatic castrate-resistant prostate cancer (mCRPC).
This study is a multi-centre, observational, retrospective research study of patients with mCRPC who have received cabazitaxel in England. Cabazitaxel is an anti-cancer chemotherapy developed by the Study Sponsor. There is currently limited multi-centre research published describing clinical experience with cabazitaxel in clinical practice in England. This study aims to describe the clinical experience with cabazitaxel in patients with mCRPC outside the confines of randomised clinical trials.
The study will take place in 5-8 centres in England and data from between 100 and 150 patients will be collected. Retrospective data will be collected from the patient's medical records by trained data collectors. All living patients who are still under the care of the participating centre will be invited to consent to allow a researcher access to their medical records for the purpose of data collection for this study. For deceased patients and those who cannot be contacted for consent, anonymised data will be collected by a member of the direct clinical care team to preserve confidentiality.REC name
South Central - Hampshire A Research Ethics Committee
REC reference
15/SC/0057
Date of REC Opinion
26 Jan 2015
REC opinion
Favourable Opinion